Gossamer Bio, Inc. stockholders approved the potential issuance of common stock pursuant to a Securities Purchase Agreement dated August 20, 2026. The approval covers shares issuable upon exercise of Pre-Funded Warrants and FDA Approval Warrants, as well as conversion of Series A-1, A-2, and A-3 Preferred Stock. These issuances would exceed 20% of the outstanding common stock prior to closing, requiring shareholder consent under Nasdaq Listing Rules 5635(c) and 5635(d). The proposal passed with 2,808,000 votes in favor against 37,814. Gossamer Bio operates as a clinical-stage biotechnology company focused on developing treatments for autoimmune diseases.
